Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The value of our amortizable intangible assets including gross asset value and carrying value is summarized below ($ in thousands):

	Bertilimumab ‎iCo			NanomAbs ‎Yissum			Human ‎Antibodies ‎Kadouche			Anti-ferritin ‎Antibody ‎MabLife			Ceplene ‎Acquisition ‎Intangibles			Total
Balance as of December 31, 2017	$	1,419		$	383		$	381		$	318		$	3,976		$	6,477
Amortization		(84	)		(24	)		(23	)		(23	)		(307	)		(461	)
Impairment		-			-			(358	)		(295	)		-			(653	)
Balance, June 30, 2018	$	1,335		$	359		$	-		$	-		$	3,669		$	5,363
Gross asset value	$	2,509		$	694		$	-		$	-		$	4,310		$	7,513
Accumulated Amortization		(1,174	)		(335	)		-			-			(641	)		(2,150	)
Balance, June 30, 2018	$	1,335		$	359		$	-		$	-		$	3,669		$	5,363

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization expense for each of the five succeeding years, based upon intangible assets at June 30, 2018 is as follows ($ in thousands):

Period Ending June 30,	Amount
2019	$	829
2020		829
2021		829
2022		829
2023		829
Thereafter		1,218
Total	$	5,363